RNTX

Rein Therapeutics, Inc. (RNTX) - 10-Q Summary for Period Ended June 30, 2025

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for Rein Therapeutics, Inc. (formerly Aileron Therapeutics, Inc.) for the period ended June 30, 2025. Rein is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrosis indications, specifically Idiopathic Pulmonary Fibrosis (IPF) and loculated pleural effusion (LPE). The company operates virtually following the expiration of its lease in March 2024. As of August 11, 2025, there were 23,305,108 shares of common stock outstanding.

Key Financial Metrics

Operating Expenses (Six Months): Research and Development (R&D) was $7.35 million; General and Administrative (G&A) was $5.13 million. Total operating expenses were $12.48 million.

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately $3.73 million compared to the prior year period, primarily driven by a significant reduction in G&A expenses ($3.91 million decrease) due to lower professional fees and employee-related costs following 2024 turnover.
• Cash Position: Cash and cash equivalents declined by $7.14 million during the six-month period, dropping from $12.87 million at year-end 2024 to $5.72 million at June 30, 2025.
• Financing Activity: Financing cash inflows decreased significantly year-over-year ($5.45 million vs. $18.26 million) as the company did not complete a major public offering in the first half of 2025, relying instead on warrant exercises and exchanges totaling approximately $4.76 million in gross proceeds in April 2025.
• R&D Spend: R&D expenses remained relatively flat ($7.35 million vs. $7.20 million), with increased spending on the LTI-03 Phase 2 trial offset by reduced manufacturing costs and write-offs compared to 2024.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash ($5.72 million) plus proceeds from a July 2025 Pre-Paid Advance ($0.95 million) are projected to fund operations only through November 2025. Additional capital is required to complete the RENEW Phase 2 trial.
• FDA Clinical Hold: On June 10, 2025, the FDA placed a clinical hold on the RENEW Phase 2 trial of lead candidate LTI-03. A formal letter dated July 8, 2025, cited inadequate nonclinical support due to the lack of a No-Observed-Adverse-Effect Level (NOAEL) in a 26-week rat study. The company is working to resolve this and plans to initiate the trial in Australia, the UK, and Europe while the US hold is active.
• Recent Financing (Subsequent Event): On July 29, 2025, the company entered into a Pre-Paid Advance Agreement (PPA) and Standby Equity Purchase Agreement (SEPA) with Yorkville. The PPA allows for up to $6.0 million in advances (initial $1.0 million drawn), and the SEPA allows for the sale of up to $15.0 million of common stock.
• Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including insufficient accounting personnel, lack of segregation of duties, and inadequate review procedures. Remediation efforts are ongoing.
• Program Status: Development of LTI-01 (for LPE) remains temporarily delayed to focus resources on LTI-03.

Key Facts for Investor Verification

• Liquidity Runway: Verify the sufficiency of the $6.67 million in available liquidity (cash + initial PPA draw) to sustain operations through November 2025 and the timeline for securing additional funding.
• FDA Resolution: Monitor the status of the clinical hold on LTI-03 and the company's progress in conducting the requested rat inhalation toxicity study to identify a NOAEL.
• Capital Raise Execution: Track the utilization of the new Yorkville SEPA and PPA facilities and any subsequent equity offerings required to fund the RENEW trial completion.
• Internal Control Remediation: Assess the progress of hiring additional accounting staff and implementing controls to address the identified material weaknesses.
• Warrant Dilution: Review the impact of outstanding warrants (approx. 6.6 million shares) and convertible preferred stock (12.2 million shares) on potential future dilution.